Search Results - "Minotti, V"

What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion by Vellucci, R., Fanelli, G., Pannuti, R., Peruselli, C., Adamo, S., Alongi, G., Amato, F., Consoletti, L., Lamarca, L., Liguori, S., Lo Presti, C., Maione, A., Mameli, S., Marinangeli, F., Marulli, S., Minotti, V., Miotti, D., Montanari, L., Moruzzi, G., Palermo, S., Parolini, M., Poli, P., Tirelli, W., Valle, A., Romualdi, P.

“…Clinical management of breakthrough cancer pain (BTcP) is still not satisfactory despite the availability of effective pharmacological agents. This is in part…”
Get full text

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations by Ludovini, V., Bianconi, F., Pistola, L., Minotti, V., Chiari, R., Colella, R., Bellezza, G., Tofanetti, F. R., Siggillino, A., Baldelli, E., Flacco, A., Giuffrida, D., Sidoni, A., Crinò, L.

“…Background We present a comprehensive analysis of KRAS , PIK3CA , MET, and non-sensitizing EGFR mutations in advanced non-small cell lung cancer (NSCLC)…”
Get full text

Erratum to: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion by Vellucci, R., Fanelli, G., Pannuti, R., Peruselli, C., Adamo, S., Alongi, G., Amato, F., Consoletti, L., Lamarca, L., Liguori, S., Presti, C. Lo, Maione, A., Mameli, S., Marinangeli, F., Marulli, S., Minotti, V., Miotti, D., Montanari, L., Moruzzi, G., Palermo, S., Parolini, M., Poli, P., Tirelli, W., Valle, A., Romualdi, P.

Get full text

Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients by Ludovini, V., Flacco, A., Bianconi, F., Ragusa, M., Vannucci, J., Bellezza, G., Chiari, R., Minotti, V., Pistola, L., Tofanetti, F. R., Siggillino, A., Baldelli, E., Sidoni, A., Daddi, N., Puma, F., Varella-Garcia, M., Crinò, L.

“…Background Insulin-like growth factor 1 receptor (IGF1R) represents a novel molecular target in non-small-cell-lung cancer (NSCLC). IGF1R and epidermal growth…”
Get full text

Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation by Metro, Giulio, Chiari, R., Mare, M., Giannarelli, D., Tofanetti, F. R., Minotti, V., Ferraldeschi, M., Giuffrida, D., Marcomigni, L., Bennati, C., Fischer, M. J., Meacci, M., Bellavita, R., Pistola, L., Ludovini, V., Crinò, L.

“…Purpose In the present study, the combination of carboplatin (CBDCA) plus pemetrexed (PMX) for the treatment of patients with platinum-pretreated,…”
Get full text

Double-blind evaluation of short-term analgesic efficacy of orally administered diclofenac, diclofenac plus codeine, and diclofenac plus imipramine in chronic cancer pain by Minotti, V, De Angelis, V, Righetti, E, Celani, M G, Rossetti, R, Lupatelli, M, Tonato, M, Pisati, R, Monza, G, Fumi, G, Del Favero, A

“…A prospective double-blind randomized trial was conducted on 184 cancer patients with moderate to severe chronic pain to evaluate the analgesic efficacy and…”
Get more information

Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer by Minotti, V, Crino′, L, Meacci, M.L, Corgna, E, Darwish, S, Palladino, M.A, Betti, M, Tonato, M

“…Twenty-three patients with brain metastases from non-small cell lung cancer (NSCLC) (median age 62 years, Karnofsky PS 50-100) were treated with cisplatin (100…”
Get full text

9050 NSCLC in never smokers, a different disease – a single institution retrospective evaluation by Minotti, V, Chiari, R, Molica, C, Betti, M, Ludovini, V, Pistola, L, Tofanetti, F.R, Flacco, A, Hamzaj, A, Crinò, L

Get full text

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1 by Besse, B., Felip, E., Garcia Campelo, R., Cobo, M., Mascaux, C., Madroszyk, A., Cappuzzo, F., Hilgers, W., Romano, G., Denis, F., Viteri, S., Debieuvre, D., Galetta, D., Baldini, E., Razaq, M., Robinet, G., Maio, M., Delmonte, A., Roch, B., Masson, P., Schuette, W., Zer, A., Remon, J., Costantini, D., Vasseur, B., Dziadziuszko, R., Giaccone, G., Zemanová, M., Besse, B., Bonnet, C., Cadranel, J., Chouaid, C., Cortot, A., Debieuvre, D., Delclaux, B., Denis, F., Duchemann, B., El Kouri, C., Ferrand, F.R., Ginoux, M., Hilgers, W., Madroszyk, A., Masson, P., Mazieres, J., Molinier, O., Moro-Sibilot, D., Pichon, E., Mascaux, C., Robinet, G., Roch, B., Zalcman, G., Schmidtke-Schrezenmeier, G., Schuette, W., Urban, L., Gottfried, M., Nechushtan, H., Peled, N., Wollner, M., Zer, A., Baldini, E., Bonanno, L., Bonetti, A., Cappuzzo, F., Delmonte, A., Galetta, D., Maio, M., Minotti, V., Rea, A., Romano, G., Tassinari, D., Tonini, G., Dziadziuszko, R., Karaszewska, B., Szczęsna, A., Cobo, M., De Castro, J., Felip, E., Garcia Campelo, M.R., Hernández, A., Moran, T., Provencio, M., Viteri, S., Dasgupta, A., Gabrail, N., Giaccone, G., Harshad, A., Liu, S., Oubre, D., Panikkar, R., Razaq, M., Sanborn, R.

“…Patients with advanced non-small-cell lung cancer (NSCLC) treated with immune checkpoint blockers (ICBs) ultimately progress either rapidly (primary…”
Get full text

Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): The SQUINT trial by Landi, L., Bonanno, L., Delmonte, A., Maximilian, P., Stati, V., Minotti, V., Bennati, C., D’Incà, F., Migliorino, M.R., Gori, S., Santo, A., Piantedosi, F., Russo, A., Cappuzzo, F.

Get full text

1595TiP - Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): The SQUINT trial by Landi, L., Bonanno, L., Delmonte, A., Maximilian, P., Stati, V., Minotti, V., Bennati, C., D’Incà, F., Migliorino, M.R., Gori, S., Santo, A., Piantedosi, F., Russo, A., Cappuzzo, F.

“…Treatment landscape for patients with advanced NSCLC is rapidly evolving, with recent randomized phase III trials demonstrating superiority of chemo-immuno…”
Get full text

Domiciliary treatment of febrile episodes in cancer patients : a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment by MINOTTI, V, GENTILE, G, DEL FAVERO, A, BUCANEVE, G, IORI, A. P, MICOZZI, A, CAVICCHI, F, BARBABIETOLA, G, LANDONIO, G, MENICHETTI, F, MARTINO, P

“…Hospitalization and empirical broad-spectrum, intravenous antibiotics are the standard treatment for febrile cancer patients. Recent evidence supports the…”
Get full text

Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer by Crinò, L, Latini, P, Meacci, M, Corgna, E, Maranzano, E, Darwish, S, Minotti, V, Santucci, A, Tonato, M

“…High-dose radiation therapy is generally recommended as standard treatment in regionally advanced unresectable non-small-cell lung cancer (NSCLC), but median-…”
Get more information

1595TiPNivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): The SQUINT trial by Landi, L, Bonanno, L, Delmonte, A, Maximilian, P, Stati, V, Minotti, V, Bennati, C, D’Incà, F, Migliorino, M R, Gori, S, Santo, A, Piantedosi, F, Russo, A, Cappuzzo, F

“…Abstract Background Treatment landscape for patients with advanced NSCLC is rapidly evolving, with recent randomized phase III trials demonstrating superiority…”
Get full text

1284P MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer by Felip, E., Minotti, V., Soo, R., Wolf, J., Solomon, B., Tan, D.S.W., Ardizzoni, A., Lee, D.H., Sequist, L.V., Barlesi, F., Paz-Ares, L., Rodriguez-Abreu, D., Campelo, M.R. Garcia, Sprauten, M., O’Sullivan Djentuh, L., Belli, R., Glaser, S., Zou, M., Giovannini, M., Yang, J.C-H.

Get full text

Clinical outcome of platinum/etoposide treated large cell neuroendocrine carcinomas of the lung according to the type of radiotherapy received: a single institution analysis by Ricciuti, B., Metro, G., Ferolla, P., Chiari, R., Paglialunga, L., Perrone, L., Currà, M.F., Giannarelli, D., Bennati, C., Minotti, V., Sidoni, A., Bellavita, R., Crinò, L.

Get full text

ROS1 rearrangement in lung adenocarcinoma: a retrospective cohort study by Bennati, C., Chiari, R., Marcomigni, L., Minotti, V., Giulio, M., Scafati, C., Matocci, R., Bellezza, G., Baglivo, S., Colabrese, D., Crinò, L.

Get full text

1297PALK AND ROS1-POSITIVE LUNG ADENOCARCINOMA (LA) PATIENT OUTCOMES: A MONO-ISTITUTIONAL EXPERIENCE by Chiari, R., Metro, G., Bennati, C., Iacono, D., Giannarelli, D., Minotti, V., Marcomigni, L., Meacci, M., Crinò, L.

“…Abstract Aim: ALK and ROS1 gene rearrangements are the “oncogenic drivers” of two subsets of LA that have been shown to be sensitive to the ALK inhibitor…”
Get full text

Alk and Ros1-Positive Lung Adenocarcinoma (La) Patient Outcomes: a Mono-Istitutional Experience by Chiari, R., Metro, G., Bennati, C., Iacono, D., Giannarelli, D., Minotti, V., Marcomigni, L., Meacci, M., Crinò, L.

Get full text

A better therapeutic profile for the combination of mitomycin-C, ifosfamide and cisplatin (MIC) in advanced non-small-cell lung cancer: A useful dose-schedule modification by CRINO, L, CORGNA, E, PORROZZI, S, PALLADINO, M. A, DARWISH, S, MINOTTI, V, MOSCONI, A. M, TONATO, M

“…In our previous experience with chemotherapy for non-small-cell lung cancer (NSCLC) the combination of mitomycin, ifosfamide and cisplatin (MIC) showed the…”
Get full text